Prototypical I1 imidazoline receptor ligand. α2-adrenergic receptor agonist. Antihypertensive. Also thought to enhance autophagy; shown to increase LC3-II levels in PC12 cells.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 266.56. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.75 mL||18.76 mL||37.52 mL|
|5 mM||0.75 mL||3.75 mL||7.5 mL|
|10 mM||0.38 mL||1.88 mL||3.75 mL|
|50 mM||0.08 mL||0.38 mL||0.75 mL|
References are publications that support the products' biological activity.
Armitsu et al (1998) Mechanism of relaxant effect of clonidine in isolated bovine tracheal smooth muscle. J.Pharmacol.Exp.Ther. 286 681 PMID: 9694921
Ernsberger et al (1987) Clonidine binds to imidazole binding sites as well as α2-adrenoceptors in the ventrolateral medulla. Eur.J.Pharmacol. 134 1 PMID: 3030779
Greney et al (1994) Isolation of a human cerebral imidazoline-specific binding protein. Eur.J.Pharmacol. 265 R1 PMID: 7883019
Silva et al (1996) Dual effect of clonidine on mesenteric artery adrenoreceptors: agonistic (alpha-2) and antagonistic (alpha-1). J.Pharmacol.Exp.ther. 277 872 PMID: 8627569
Williams et al (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat.Chem.Biol. 4 295 PMID: 18391949
If you know of a relevant reference for Clonidine hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Clonidine hydrochloride, supplier, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenergic, α2-Adrenergic, alpha2-Adrenergic, a2-adrenoceptor, agonists, I1, ligand, Receptors, Imidazoline, Adrenergic, Alpha-2, Receptors, I1, Receptors, Autophagy, Adrenergic, Alpha-2, Receptors, Tocris Bioscience
6 Citations for Clonidine hydrochloride
Citations are publications that use Tocris products. Selected citations for Clonidine hydrochloride include:
Cinelli et al (2013) Suppression of the cough reflex by α 2-adrenergic receptor agonists in the rabbit. Physiol Rep 1 e00122 PMID: 24400133
Liu et al (2011) Ongoing pain in the MIA model of osteoarthritis. Neurosci Lett 493 72 PMID: 21241772
Kim et al (2011) Icilin-evoked behavioral stimulation is attenuated by alpha2-adrenoceptor activation. Brain Res 1384 110 PMID: 21315691
Okun et al (2011) Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents. Purinergic Signal 7 4 PMID: 21219650
Devoto et al (2015) Selective inhibition of dopamine-β-hydroxylase enhances dopamine release from noradrenergic terminals in the medial prefrontal cortex. Mol Pain 5 e00393 PMID: 26516613
Garzón et al (2009) Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Mol Pain 5 11 PMID: 19284549
Do you know of a great paper that uses Clonidine hydrochloride from Tocris? If so please let us know.
Clonidine hydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.